Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MST1R |
| Variant | act mut |
| Impact List | unknown |
| Protein Effect | gain of function |
| Gene Variant Descriptions | MST1R act mut indicates that this variant results in a gain of function in the Mst1r protein. However, the specific amino acid change has not been identified. |
| Associated Drug Resistance | |
| Category Variants Paths |
MST1R mutant MST1R act mut |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MST1R act mut | breast cancer | predicted - sensitive | BMS-777607 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, BMS-777607 (ASLAN002) inhibited tumor growth in breast cancer cell line xenograft models expressing a constitutively active short isoform of MST1R (RON) (PMID: 26289070). | 26289070 |
| MST1R act mut | breast cancer | predicted - sensitive | OSI-296 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, OSI-296 inhibited tumor growth in breast cancer cell line xenograft models expressing a constitutively active short isoform of MST1R (RON) (PMID: 26289070). | 26289070 |
| MST1R act mut | breast cancer | predicted - sensitive | BMS-777607 + Buparlisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of BKM120 and BMS-777607 (ASLAN002) inhibited tumor growth in breast cancer cell line xenograft models expressing a constitutively active short isoform of MST1R (RON), with increased efficacy over either agent alone (PMID: 26289070). | 26289070 |